Cymbalta - Case Study

There are multiple health concerns worldwide and more and more drugs are needed every day. Many drugs however, are extremely expensive to develop, test, and produce. According to the Tufts Center for the Study of Drug Development (2002), it costs up to $802 million to bring a new drug to the market. In 2002, pharmaceutical companies spent $34 billion in research and development (Center-Watch, 2003). In addition to the costs, the overall time from the discovery to approve and market the drug can take up to 15 years.

This review provides an in-depth strategic SWOT analysis of the company’s businesses and operations in the areas of internal strengths and weaknesses and external opportunities and threats. (Sector Publishing Intelligence)

Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation and

We in America tend to take medications for almost any problem we have, from headaches to gastrointestinal pain, to more serious chronic disorders such as depression and attention deficit disorder. While many of the uses of such medications may be necessary and legitimate, many are not, and due to this fact, many people become dependent on medications, mentally, and or physically. This problem is not simply the fault of the individual; in fact, the blame can also be placed upon the medical community, and the pharmaceutical companies who produce the drugs. How often can one turn on the television to see advertisements for Claritin, Aspirin, Pepto-Bismol, or even Zoloft or Ritalin? The pharmaceutical industry is motivated by monetary

When examining the potential for a new business or product, a SWOT analysis can help determine the likely risks and rewards. A SWOT analysis is an organized list of a business’s greatest strengths, weaknesses, opportunities, and threats. Strengths, which are the appearances of the business that give it an advantage over others, and weaknesses, which are features that place the team at a disadvantage, are internal to the company and can be changed over time but not without some work. Opportunities, which are basics that the business could use to enhance its strengths, and threats, which are elements in the environment that could cause concern for the business, are external and they are out there in the market,

Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well

Companies stand to lose a lot of profits once the patent expires on a widely used drug. The hugely popular antidepressant Prozac was a drug about to lose its patent, so what could the company do? They didn't want to lose millions of dollars did they? The company came up with a new plan, they created a new condition, PMDD (Pre-Menstrual Dysphoric Disorder), and then went to the FDA and doctors with their highly paid "experts" who convinced them that PMDD is a tragic disease. Their plan worked and got the "new" drug Sarafem (the same drug)

Recently, there has been a debate about the high prescription drug prices in the United States. Accounting for 9.7% of the national health expenditure, $329.2 billion was spent on prescription medications ($931 per person) in 2011 (Linton, 2014). So what exactly is the average American getting with their $931? Well, because there is an extraordinary amount of time, effort, and energy that goes into creating, manufacturing, and distributing a new drug, it’s no wonder the prices are so high. But what other costs are folded into the prices of your prescribed medications? This review looks beyond just the research and development costs needed to take a new drug from idea to shelf by examining several journals and other credible, secondary sources, to shed some light on how much pharmaceutical companies are spending to develop, advertise, and sell their drugs.

The SWOT analysis, taking a look at how a business translates external threats and opportunities, and responds taking into account weaknesses and strengths. It is better utilised for deciding a marketing strategy, to see where the organisation is performing admirably, and where they are performing inadequately. This analysis takes a look at Mulberry and what risks they gain from opportunities, and what keeps them away from changing a weakness.

The pharmaceutical industry has become the major player in medicalization. Every day we are bombarded with commercials on the TV advertising medications for sleep, depression, erectile dysfunction and so on. There are so many

We anticipate potential competitions from organizations or other newly established companies developing new targeted therapies. We expect to compete with

When one has  a major depressive disorder they can exhibit several behaviors such as depressed mood, feel guilt or shame, suicidal thoughts or self-neglect, low self-esteem, loneliness, negative outlook on everything. They can also show fatigue, sleeping problems, appetite increase or decrease, loss of sex drive and mental and physical slowing down or agitated. There are a few treatments for this disorder such as psychotherapy, antidepressant medications, electroconvulsive treatment (ECT), and other somatic therapies. One of the most recognized drugs used to treat MDD is Cymbalta. Cymbalta is used to help regain chemical balance in the brain that is thought to cause MDD. This medication is taken orally and

Furthermore, as universities increase student enrollment, the university will require additional supplies for research projects. This compels administration to seek funding rather than searching for ways to benefit society. In addition, causing problems between colleagues and various departments, however, keep in mind when one department receives funding over another due to Government influences, the smaller departments are still funded by smaller organizations. Furthermore, the government is trying exert certain departments to distribute their findings. The rise to commercialize research has been ongoing since the 1980's. In 2002 the Association of Universities and Colleges of Canada, along with the government, assembled a meeting to discuss commercialization and the "major" research departments. The three companies emplaced an alliance stating the Universities will receive double the funding for research departments, in return tripling the commercialization. Interestingly, the department faculties were not in attendance for this conference; whom are considerable contributors to the commercialization of funded project. The government has already capitalized peoples well–being in regards to mental health as demonstrated by commercialized products. Therefore, anti-depressants drugs are endorsed because they are commercialized. Not addressing that mental health can be approached in various ways. However, the evidence is rising that such natural products can

SWOT Analysis: The internal strengths and weaknesses of the company, and the external opportunities and threats from the viewpoint of the company

Only a small fraction of all drugs investigated for use in humans are actually approved. Those that fail part-way in this process incur high costs with virtually zero revenue in return. Capital must be invested years before revenues become realized; further increasing costs if recognizing the time value of money. Recent years have shown increases in mergers and acquisitions within the industry. Mergers and acquisitions play a crucial role in the pharmaceutical industry, largely a result of research, development, and production costs. Frequently a smaller company will develop a new drug but be without the capital needed to introduce it into the market. Larger companies often have unused capacity in their sales and marketing force, so it may be in the interest of both companies to conglomerate horizontally. Patents play another crucial role in the pharmaceutical industry. A company may apply for a patent for a new drug, thus getting exclusive rights for about 20 years. Companies use this period to recover costs of research and development. When this patent expires, competing companies release generic versions of the drug, increasing competition dramatically. Competitive Summary Competition within the pharmaceutical industry is rigorous among the industry’s leading institutions. Research and development, firm size, advertising, and productivity are the driving forces for success (The American Economist, 2006). The effects of globalization and intellectual